Product Description
Huabo bio is developing HB0045, a CD73 Inhibitor. (Sourced from: http://www.huabobio.com/en/upload/2022/06/10/16548404197366dtjy6.pdf)
Mechanisms of Action: CD73 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Huabo Biopharm Co., Ltd.
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Colorectal Cancer|Ovarian Cancer|Pancreatic Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| HB0045-01 | P2 |
Recruiting |
Colorectal Cancer|Ovarian Cancer|Pancreatic Cancer |
2025-09-19 |
2023-10-24 |
Primary Endpoints|Start Date|Treatments|Trial Status |
|
| HB0045-01 | P2 |
Not yet recruiting |
Pancreatic Cancer|Ovarian Cancer|Colorectal Cancer |
2025-08-19 |
32% |
2023-07-14 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|